The Subject Expert Committee of the Central Drugs Standard Control Organisation will allow the Serum Institute of India to conduct trials of the Novavax COVID-19 vaccine in children between the ages of 7 and 11 years.
The Subject Expert Committee of Central Drugs Standard Control Organisation allows Serum Institute of India to conduct trials of the Novavax COVID-19 vaccine for children aged 7 to 11 years old.
The Subject Expert Committee of theCentral Drugs Standard Control Organisation willallow theSerum Institute of India to conduct trials of the Novavax COVID-19 vaccine in children betweentheagesof7 and 11 years.
